Best Oncology Companies in British Columbia, Canada
The 44 best Oncology companies in British Columbia, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Virogin Biotech.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in British Columbia
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Virogin Biotech Developed of drugs for the treatment of cancer | $281M | 59 mo ago | 56 | William Jia Co-Founder | 103 patents Engineered oncolytic viruses for targeted cancer immunotherapy and HPV-associated malignancies | — |
| 2 | Zymeworks Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 32 mo ago | 277 277 → 271 (-2%) | — | 1,015 patents Design and production of multispecific therapeutic antibodies targeting cancer antigens | — |
| 3 | Abdera Therapeutics Provider of therapeutics for cancer treatment. | $142M | 40 mo ago | 20 | Adam Judge Co-Founder | 9 patents Targeted radioimmunotherapy using DLL3-specific antibody fragments and chelator conjugates | — |
| 4 | Abcellera Biologics AI-enabled platform for antibodies discovery | $115M | 62 mo ago | 560 | — | 50 patents Therapeutic antibody discovery using transgenic rodents and computational affinity modeling | 1 partnership |
| 5 | Alpha-9 Theranostics Developer of molecules for solid and hematologic malignancies | $84M | 44 mo ago | 24 | Ian McBeath CEO | 6 patents Radiolabeled PSMA and CXCR4 ligands for targeted cancer imaging and therapy | — |
| 6 | Angle Developer of cancer cell capture and analysis equipment | $81M | 49 mo ago | 176 | — | — | — |
| 7 | ProNAi Therapeutics Developer of DNA-based gene therapies for cancer and other genetic diseases | $77M | 148 mo ago | — | Nick Glover President and CEO | — | — |
| 8 | Sierra Oncology Developer of targeted therapies to treat cancer | $75M | 147 mo ago | 109 | — | — | — |
| 9 | Aquinox Pharma Small molecule targeting PI3K pathway. | $71M | 160 mo ago | — | — | — | — |
| 10 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 53 mo ago | 22 | — | 80 patents Innate immune modulation for adoptive cell therapies and perioperative cancer treatment | — |
| 11 | ESSA Pharma Developer of small molecule drugs for the treatment cancer | $16M | 67 mo ago | 28 | David Parkinson President & Chief Executive Officer | 91 patents Developing androgen receptor inhibitor drugs and solid formulations for cancer therapy. | — |
| 12 | Phoenix Molecular Designs Developer of small molecule kinase inhibitors for the treatment of cancer | $15M | 81 mo ago | 12 | — | 34 patents Patents concentrated in health & consumer products | — |
| 13 | Reverb Therapeutics Developer of treatments for cancer and other diseases | $12M | 18 mo ago | — | Surjit Dixit Co-Founder | — | — |
| 14 | Rakovina Therapeutics Developer of precision medicine to kill cancer cells 27Funding top 37%Patents top 40%Tech top 46%Growth top 47% All 9 signals ▾Fundingtop 37% Patentstop 40% Techtop 46% Growthtop 47% Newstop 48% Moatbottom 49% Innovationbottom 48% Globalbottom 35% Marketbottom 18% Funding: Raised $7.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 9 patents matched (strict assignee match) · 8 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $8M | 15 mo ago | 6 | — | 9 patents Dual-target PARP/HDAC inhibitors for oncology, especially Ewing sarcoma and solid tumors | — |
| 15 | DelMar Pharmaceuticals Developer of drug candidates targeting orphan cancer indications | $8M | 72 mo ago | 3 | — | 24 patents Patents concentrated in health & consumer products | — |
| 16 | Bold Therapeutics Developer of therapeutics for the treatment of cancer | $5M | 67 mo ago | 16 | Russell Mcallister President and CEO | 44 patents Patents concentrated in chemistry & materials | — |
| 17 | Biomark Diagnostics Provider of metabolomics-based diagnostics for cancer | $5M | 17 mo ago | 6 | — | — | — |
| 18 | Mesentech Developer of therapies for treating bone disorders | $4M | 19 mo ago | 13 | Ian McBeath Founder & Co-CEO | — | — |
| 19 | Sitka Biopharma Canadian, early-stage biopharma developing polymeric nanoparticle-based chemotherapeutics. | $3M | 90 mo ago | 4 | — | — | — |
| 20 | Med BioGene Provider of genomics-based test for the detection of early-stage lung cancer | $3M | — | 7 | — | — | — |
| 21 | PreveCeutical Developer of peptide based therapuetics for cancer treatment | $2M | 14 mo ago | 7 | Mak Jawadekar Co-Founder | — | — |
| 22 | LED Apteryx Imaging solutions for dental diagnostics | $2M | 105 mo ago | — | Lamar Roberts CEO | — | — |
| 23 | TheraPten Developing PTEN-L, a natural human anti-cancer tumour suppressor protein, as an injectable biological therapy. | $2M | 98 mo ago | 2 | Nassos Alevizopoulos Co-Founder & CEO | — | 1 launch |
| 24 | Verisante Cancer detection platforms | $1M | 49 mo ago | 18 | — | 8 patents Spectral calibration standards and endoscopic reflectance imaging for cancer detection. | — |
| 25 | Augurex Developer of diagnostic tests to detect autoimmune and chronic diseases | $978K | 186 mo ago | 20 | — | — | 1 award |
| 26 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 17 mo ago | — | Dominique Cheneval President and Co-Founder | 21 patents Small‑molecule benzopyran therapeutics and assays targeting mRNA stability modulation | — |
| 27 | KOP Therapeutics Developer of genetic modification therapy for the cancer | $114K | 78 mo ago | — | Tibor Gajdics Founder & CEO | — | — |
Top 12 Oncology companies in British Columbia
#1
Public · Vancouver, British Columbia · founded 2020 · 6 employees$7.9Mraised▾
Developer of precision medicine to kill cancer cells. The company has biomarker-driven, next-generation PARP-inhibitor therapeutics that include KT-2000, KT-3000, and KT-4000. It releases a DNA-damaging agent, which inhibits the DNA damage repair pathway and kills cancer cells.
- May 2025Post IPO$2.9M
- Jan 2025Post IPO$1.5M
- Dec 2024Post IPO$2.1M
- May 2024Post IPO$1.5M
#2
Public · Richmond, British Columbia · founded 2007 · 6 employees$5.3Mraised▾
Provider of metabolomics-based diagnostics for cancer. Its proprietary technology involves measurement of levels of aceylated levels of the drug Amantadine, administered to patients prior to testing. Acetylation occurs due to the presence of Spermidine N-Acetyl Transferase (SSAT),which is elevated in many cancers including lung, breast, melanoma, GI and others.
- Mar 2025Post IPO$2.5M
- Apr 2024Grant (prize money)$290K
- May 2022Post IPO$1.2M
- Jun 2021Grant (prize money)$683.4K
#3
Public · Vancouver, British Columbia · founded 2015 · 7 employees$2.3Mraised▾
PreveCeutical is a developer of peptide-based therapeutics for cancer treatment. The company's lead product candidate CellB9 contains peptides from the Caribbean Blue Scorpion and is used for the treatment of cancer. These peptides have immune-boosting, pain-relieving, and tumor-selective properties. The company is also developing peptide drugs for pain management. It has also developed a Sol-Gel delivery platform for the delivery of cannabis and CBD-based drugs for the treatment of pain, inflammation, seizures, and neurological disorders.
- Jun 2025Post IPO$547.7K
- May 2025Post IPO$114.3K
- Apr 2025Post IPO$426.5K
- Jun 2019Conventional Debt$300K
#4
Seed · Vancouver, British Columbia · founded 2022$12Mraised▾
Developer of treatments for cancer and other diseases. It offers Amplifier Antibody platform that avoids the systemic toxicity normally associated with cytokine treatments by increasing cytokine levels only in targeted tissues.
- Feb 2025Seed$12M
- Nov 2023Seed—
#5
Series A · Vancouver, British Columbia · founded 2016 · 13 employees$3.9Mraised▾
Developer of therapies for treating bone disorders. The company's lead candidate is MES1007, a bone-targeted prodrug that has the potential to reverse bone loss caused by diseases such as Duchenne muscular dystrophy and osteoporosis. Also, it leverages bi-specific drug conjugate technology to develop new drugs for hematological and gastrointestinal diseases.
- Jan 2025Series A$2.3M
- Nov 2024Series A$1.2M
- Apr 2022Series A$3.9M
- Nov 2020Seed—
#6
Public · Vancouver, British Columbia · founded 2003 · 277 employees$146Mraised▾
Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. The company’s Azymetric and AlbuCORE platforms, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
- Dec 2023Post IPO$50M
- Jan 2016Series A$61.5M
- Feb 2015Series A$1.8M
- Jan 2015Series A$24M
#7
Series B · Vancouver, British Columbia · founded 2020 · 20 employees$142Mraised▾
Provider of therapeutics for cancer treatment. It has ROVEr platform which integrates antibody engineering with radionuclide payloads aiming to deliver either alpha- or beta-emitting radioisotopes selectively to tumour cells. It offers a lead clinical program is ABD 147 for small cell lung cancer and large cell neuroendocrine carcinoma, and ABD 320 targeting multiple cancer types.
- Apr 2023Series B$110M
- 2021Series A$32.5M
- Jan 2021Seed$6.3M
#8
Funding Raised · Burnaby, British Columbia · founded 1999$625.5Kraised▾
Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform. The company is using its proprietary technology Quest to discover small molecules. The technology involves identification of mRNA stability regulatory elements (SCEs); cloning of the target SCE into a relevant diseased cell and then the production of stable cell line; screening of compound libraries.
- Mar 2025Grant (prize money)$625.5K
#9
Series D · Vancouver, British Columbia · founded 2015 · 56 employees$281Mraised▾
Virogin is a developed of drugs for the treatment of cancer. It has developed immuno-oncolytic therapeutics for the treatment of tumor cells. Its lead product VG161 has entered Phase I clinical trials. It provides a Synerlytic platform that enhanced activation of both innate and adaptive immunity without stimulating MDSCs and T-regs favors higher recruitment of cytotoxic immune cells to the tumor microenvironment. It increases oncolysis releases more inaccessible tumor antigens, promoting a longer-lasting, tumor antigen-specific immune memory response.
- Sep 2021Series D$127M
- May 2021Series D$80M
- Sep 2020Series C$62M
- Feb 2017Series A$5M
#10
Public · Surrey, British Columbia · founded 1994 · 176 employees$81.4Mraised▾
Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.
- Jul 2022Post IPO$23.7M
- Oct 2020Post IPO$25.9M
- Jun 2018Post IPO$14.8M
- Jan 2018Grant (prize money)$557.5K
#11
Series B · Vancouver, British Columbia · founded 2019 · 24 employees$83.9Mraised▾
Developer of molecules for solid and hematologic malignancies. It offers peptide-based radiopharmaceuticals iwhich includes prostate specific membrane antigen, prostate specific membrane antigen, C-X-C chemokine receptor type 4, bradykinin B1 receptor and others for therapeutic and diagnostic purpose.
- Dec 2022Series B$75M
- Apr 2021Series A$8.9M
#12
Public · Vancouver, British Columbia · founded 2012 · 560 employees$115Mraised▾
AI-enabled platform for antibodies discovery. The company has developed Celium which is an antibody visualization software and suite of proprietary microfluidic single-cell assays used for antibody screening. The company uses its proprietary repertoire sequencing technologies with functional data from single B cells to annotate immune repertoires. It has also developed its proprietary humanized mouse platform for the development of humanized antibodies.
- Jun 2021Post IPO—
- May 2020Grant (prize money)$124M
- Mar 2020Series B$105M
- Aug 2018Series A$10M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Canada
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,276 Canada-affiliated papers.
- Ministry of Education247
- University of Toronto121
- McGill University107
- Princess Margaret Cancer Centre93
- Institute of Cancer Research91
- Tumor microenvironment9→204
- Immune system2→159
- Cancer research14→135
- Immunotherapy1→113
- Cancer immunotherapy1→65
- Tumor microenvironment11→286
- Immune system11→223
- Immunotherapy7→184
- Cancer research17→177
- Cancer immunotherapy3→68
- Immunotherapy2→72
- Tumor microenvironment4→63
- Immune system3→60
- Cancer immunotherapy1→29
- Cancer research2→24
Where oncology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in Canada
Canada oncology patent filing is accelerating — 81 filings from 30 assignees (2017–2025), led by Fusion Pharmaceuticals, Lilly ELI, Zymeworks; annual filings 2→6.
- Fusion Pharmaceuticals35
- Lilly ELI20
- Zymeworks18
- The Royal Institution For The Ad9
- Turnstone7
- UNIV Laval5
- Grinshtein Natalie4
- Burak ERIC Steven4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.